Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidilizumab and Dendritic Cell Vaccine in Multiple Myeloma Post-ASCT
NCT01067287Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2010
- Primary completion
- Sep 2025
- Modality
- Whole Cell Cancer Vaccines, Patient-derived iPSCs, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 2
01
Overview
A Phase 2 trial of pidilizumab, dendritic cell fusion vaccine in multiple myeloma (MM), sponsored by Beth Israel Deaconess Medical Center. Started Mar 2010; status: completed.
02
Drugs
pidilizumabdendritic cell fusion vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01067287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01067287.